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EXTREME HYPERKALAEMIA SECONDARY TO MALIGNANT
URETERIC OBSTRUCTION: CASE REPORT
Y. ALI, R.K. GUPTA, E.O. KEHINDE and K.V. JOHNNY
SUMMARY
We report a case of a 42 year old patient who collapsed at an airport departure lounge. The patient
was investigated and found to have advanced renal failure with serum potassium (K
+
) of 10.3
mmol/L, creatinine of 3581 µmol/L and urea of 59.9 mmol/L secondary to obstructive uropathy due
to advanced bladder cancer. Although these biochemical changes were thought to be incompatible
with life, he made a slow recovery following haemodialysis and insertion of bilateral percutaneous
nephrostomy tubes.
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INTRODUCTION
Hyperkalaemia is defined as plasma or serum K
+
greater than 5.3  mmol/L. Serum K+ of 5.3 - 6.5
mmol/L is considered mild hyperkalaemia, and
above 6.5 mmol/L as severe hyperkalaemia.
Extreme hyperkalema is defined as K
+
 greater than
9.0 mmol/L because such levels of serum K
+
 may
be considered incompatible with life, with less than
six patients having survived such levels, according
to the available medical literature (1-4). We described
the successful resuscitation techniques employed in
a patient who collapsed at an airport departure
lounge and was found to have serum K
+
 of
10.3 mmol/L in addition to other biochemical
abnormalities associated with advanced renal
failure.
CASE REPORT
R.A.A, a 42-year old Egyptian man was brought
from the airport departure lounge to the emergency
room with a history of sudden loss of consciousness
while waiting to board an aircraft. Prior to admission
the patient was said to be complaining of bilateral
loin pain, obstructive lower urinary tract symptoms,
drowsiness, poor appetite, lethargy and generalised
weakness for which he attended different hospital
casualty departments, where he was given
symptomatic treatment. He had urinary
schistosomiasis in childhood and was a heavy
smoker for about 25 years.
On physical examination he had shallow
acidotic breathing. His blood pressure was 140/80
mmHg; pulse was 108/minute and temperature was
38ºC. His consciousness level according to the
Glasgow coma scale was 5/15. He was intubated
immediately, mechanically ventilated, and admitted
to the intensive care unit (ICU).
Initial laboratory investigations results were as
follows: haemoglobin; 8.9 gm/dL, platelets; 286 ×
l09/L, serum K
+ l0.3 mmol/L (normal range 3.5-5.3),
serum creatinine 3581 µmol/L (normal range 60-110)
and serum urea 59.9 mmol/L (normal range 2-6).
Arterial blood gas-analysis showed a pH of 6.8 and
other gross abnormal changes (Table 1). ECG
showed peak T wave and supraventricular
tachycardia.
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The patient was put on fluid resuscitation, i.v.
Rocephine 2g OD and H2-receptor blocker (i.v
zantac 50mg 8 hourly) to prevent stress ulcer.
Emergency haemofiltration was carried out.
Following this, there was a mild improvement in
his blood biochemistry and serum K
+
 fell to 9.9
mmol/L and serum creatinine fell to 2883 µmo1/L.
Subsequently, the patient had emergency
haemodialysis and this resulted in rapid lowering
of K
+ from 9.9 to 5.9 mmol/L within a 12 hour period
(Table 2). Ultrasound of the abdomen, kidneys,
ureters and bladder revealed bilateral huge
hydronephrosis with loss of parenchyma (left>
right), thickened bladder wall and a mass in the
bladder.
After resuscitation and haemodialysis, his
biochemistry improved and on the third post
admission day, bilateral percutaneous nephrostomy
(PCN) tubes were inserted. Following the PCN, the
patient had post obstructive diuresis and after seven
days, the serum creatinine had stabilised at
170 µmol1/L and K+ at 4.3 mmol/L (Table 2).
Creatinine clearance was 10 ml/minute from the left
kidney, and 37.4 ml/minute from the right kidney.
Bilateral antegrade study through the PCN tubes
showed complete bilateral ureteric obstruction at the
level of the sacro-iliac joints. Diuretic renogram
revealed poor-functioning left kidney, with 12%
function while the right kidney had a function of
88%, with evidence of obstruction on both sides. Ten
days after successful resuscitation, under general
anaesthesia, cystoscopy revealed a bladder filled
with a necrotic mass,which was a non-papillary
infiltrating tumour. Biopsies were taken.
Examination under general anaesthesia revealed
posteriouly indurated and fixed bladder wall.
Table 2
Changes in haematological and biochemistry profiles of the patient on admission with treatment
Substance Day / Time
Day 1 Day 1 Day 1  Day 1 Day 2 Day 3 Day 6 Day 32
7.30 am 11.30 am 5 pm 12 midnight
WBC × 109/L 27.8 24.7 23.4 19.6 17.6 13.1 6.7
Hb (gm/dL) 8.7  9 8.4 8.8 8.5 10.1 10.5
Platelets 109/L 253 265 238 222 203 225 175
BUN (mmol/L) 59.9 44.8 42.9 29.7 31.7 33.7 7.6 6.5
Creatinine (µmol/L) 3581 3236 2387 2043 1776 1839 170 170
Potasium (mmol/L) 10.3 9.9* 6.2* 5.9* 4.6 4.8 4.5 4.3
* rapid reduction of K
+
 level with haemodialysis
Table 1
Changes in blood gases of the patient on admission and with treatment
Substance Day / Time
Day l Day 2 Day 3 Day 3 Day 4 Day 5
 am  pm
PH  6.8 7.17 7.20 7.20  7.2  7.3
PCO2 5.45 38.1 45.7 35.72 38.1 31.2
PO2 16.29  192  185  154 86.8 115.6
HCO3 13.9 13.8  18.  15 15.4 15.4
BE -14 -13.7 -9.5 -11 -11 -9.5
SAO2 97.8 99.2 98.8 93.5 97.8
BE = Base Excess
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Histology revealed poorly differentiated
squamous cell carcinoma of the bladder with
schistosoma ova in the bladder wall. Bone scan
revealed no scintigraphic evidence of skeletal
metastases. CT-scan of the abdomen and the pelvis
confirmed bilateral hydronephrosis, (left> right) and
a bladder tumour invading the rectum (stage
T4NxMo). The patient refused definitive treatment
planned in our unit (palliative cystectomy and ileal
conduit). He opted to return to his native country
to continue treatment. He was discharged on day
32 with bilateral PCN tubes, serum creatinine of
170 µmol/L and haemoglobin of 10.5 gm/dL.
DISCUSSION
Hyperkalaemia is a life threatening, potentially fatal
condition, mainly due to severe cardiac arrhythmias
and other ECG changes, including asystole which
can occur depending on the severity and rapidity
of development of the hyperkalaemia, as well as the
presence of other electrolytes disorders and whether
appropriate and prompt treatment had been carried
out (5). Progression from mild to severe
hyperkalaemia can lead to benign ECG changes
being transformed to lethal arrhythmias. The kidney
is the main regulator of serum potassium
concentration and hyperkalaemia is, therefore, not
a rare condition in the hospitalised patient
population, especially those with renal disorders.
K
+
 is the major intracellular cation. The total
body content is about 3500 mEq (or 50mEq/Kg body
weight), 90% of which is intracellular, and only 2%
of body potassium is in the extracellular fluid. Its
concentration is finely regulated by the flux of K
+
between the extracellular and intracellular space
(internal K
+
 homeostasis). Hyperkalaemia is
worsened by the redistribution of potassium
between intra-and extracellular compartments
caused by acidosis (6). In our patient there was
obstructive uropathy, renal shutdown, severe
dehydration and acidosis all of which could explain
the patient’s hyperkalaemia.
Treatment modality for hyperkalaemia varies
depending on the severity, the renal function status
and whether the patient is oliguric or polyuric (7).
Haemodialysis is a correct approach for the treatment
of hyperkalaemia in patients with renal failure. Any
ECG manifestation more severe than peaked T- wave
should be treated with intravenous calcium gluconate
to allow cell membrane stabilization (8). Serum K+
may also be reduced by administration of intravenous
insulin, together with glucose to prevent
hypoglycaemia. Insulin stimulates the Na-K ATPase
pump driving K+ into the cells. Intravenous sodium
bicarbonate decreases serum K+ by causing a shift of
K+ into the cell. The Na-K ATPase pump may also be
stimulated by B2 adrenergic receptor agonists. Mild
hyperkalaemia may be treated with the
administration of cation exchange resins, and in non
oliguric patients, frusemide may reduce serum K+ by
increasing urinary potassium excretion. Life
threatening hyperkalaemia (K+>9mmol/L) is often
drug induced such as those encountered during
combined therapy with angiotensin converting
enzyme (ACE) inhibitors and spironolactone (3,4).
Most cases of extreme hyperkalaemia have been seen
in patients on ACE inhibitors and spironolactone,
frusemide or encountered as a feature of
hyperglycaemia or of poorly managed end stage renal
failure (ESRF) (2,3). Exacerbating factors include renal
insufficiency or concomitant intake of K+ retaining
drugs (1). Hence, it has been advocated that the
combination of spironolactone and ACE inhibitors
should be used with caution, monitored closely in
patients with renal insufficiency, intercurrent disease,
worsening heart failure, old age, DM or simultaneous
intake of other drugs that may cause hyperkalaemia.
Furthermore, spironolactone dose above 25 mg/day
should be avoided. The highest recorded survivable
serum K+ was 14 mmol/L, but this may be considered
to be iatrogenic in origin since the patient had such
high K+ level sequel to massive rhabdomyolysis
sustained during the trauma of cardiopulmonary
resuscitation and external defibrillation as well as
prolonged ischaemia (1). Furthermore, this case
occurred while the patient was being actively
resuscitated in an ICU. Four other cases of extreme
hyperkalaemia had serum K+ levels of 9.1, 9.3, 9.3,
9.4 mmol/L and were reported in patients with
poorly managed haemodialysis, DM + ESRF, ACE
inhibitor and ESRF and on a patient on ACE inhibitor
and severe diarrhoea respectively (2,3,9,10). Hence,
the case being reported must be about the sixth case
in the literature of extreme hyperkalaemia. Our case
is unique in that the patient did not have any pre-
existing renal disease and was not on any medication.
This case also demonstrates that, K+ level of >10.0
mmol/L can be considered levels at which a patient
may die if not due to cardiac complications like severe
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dysrrhythmia, ventricular fibrillation or asystole, the
previously thought cause of death in patients with
hyperkalaemia (11,12), but secondary to other
associated biochemical changes (Tables 1 and 2).
These changes often result in severe loss of
consciousness as our patient when first seen with a
Glasgow coma scale of five was initially thought to
have had a sudden catastrophic cerebrovascular
accident or myocardial infarction. For patients with
severe or extreme hyperkalaemia, haemodialysis
should be regarded as the treatment of choice and
started as soon as possible. Effective haemodialysis
as our case demonstrates results in rapid lowering of
serum K+ level in these seriously ill patients.
In conclusion, although hyperkalaemia is a
potentially lethal condition, and frequently
encountered in hospitalised population, it can be
treated successfully by pre-emptive measures prior
to embarking on haemodialysis which is the best
modality of treatment for severe/extreme
hyperkalaemia. Severe electrolyte disturbances may
be another cause of death in cases of extreme
hyperkalaemia when cardiac dysrrthymia does not
result in the death of the patient.
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